SUBSCRIBE
SUBSCRIBE

Postmarket research

Business
After Rova-T Failure, A Look at AbbVie’s Pipeline
Analysts look at what else AbbVie has in the pipeline after Rova-T Failure.
March 27, 2018
 · 
2 min read
 · 
Mark Terry
3 Biotechs That Got Huge Boosts From Spark's FDA P
Drug Development
Sarepta Plunged After Adverse Event Forces Trial Halt in the UK
But the biotech swiftly indicated that it doesn’t expect the halt to last for long.
February 12, 2018
 · 
2 min read
 · 
Mark Terry
Drug Development
Novartis’ New Year Continues With Second FDA Breakthrough Tag of the Week
A Novartis drug approved as a second-line treatment for a blood disorder snagged the FDA’s Breakthrough Therapy Designation as a first-line defense.
January 4, 2018
 · 
2 min read
 · 
Alex Keown
Voyager Sinks as Sanofi Genzyme Opts Out of Parki
Drug Development
Sanofi Takes a $120M Hit as Potential Dengue Vaccine Blockbuster Dealt Safety Blow
Sanofi’s setback could open the door for rival drugmaker Takeda.
November 30, 2017
 · 
2 min read
 · 
Alex Keown
Drug Development
GeneSight Shown to Statistically Significantly Improve Generalized Anxiety Disorder Treatment Response and Decrease Benzodiazepine Use
Assurex Health, a wholly-owned subsidiary of Myriad Genetics, today announced new positive results for the GeneSight test in patients with Generalized Anxiety Disorder (GAD).
October 20, 2017
 · 
5 min read
Drug Development
Novartis Drug Revolade Shows Long-Term Disease Control for Chronic/Persistent Immune Thrombocytopenia (ITP)
The long term study results were published online in Blood.
October 18, 2017
 · 
14 min read
Drug Development
BioPharm Executive: From the Bench to the Clinic
Alnylam’s victory with Patisiran in familial amyloid polyneuropathy (FAP) is significant for more than just the company and its patients.
October 14, 2017
 · 
1 min read
 · 
Karl Thiel
Drug Development
Johnson & Johnson’s New Xarelto Data Could Bring In $1.5 Billion In The U.S. Alone
August 28, 2017
 · 
1 min read
Why This Tiny Biotech is Giving Cash to Amgen Researchers
Drug Development
UCSF Heart Doctor Wary of Amgen-Paid Repatha Study
March 22, 2017
 · 
3 min read
Why This Tiny Biotech is Giving Cash to Amgen Researchers
Drug Development
Disappointment Hits as Amgen’s Repatha Prevents Heart Attacks, But Not Deaths
March 17, 2017
 · 
4 min read
Load More
PRESS RELEASES
News
Tenon(R) Medical Announces First Peer Reviewed Publication of the MAINSAIL(TM) Study Analyzing the First 33 Consecutive Patients from an IRB Approved, Prospective, Multi-Centered, Post-Market Clinical Investigation Utilizing the Catamaran(R) SI Joint Fusion System
September 6, 2024
 · 
8 min read
Drug Development
Corcept Completes Enrollment in Phase 4 CATALYST Trial
April 29, 2024
 · 
3 min read
Business
Parexel and Palantir Expand Collaboration to Accelerate Clinical Data Delivery and Power Clinical Outcomes for Patients
April 25, 2024
 · 
6 min read
Drug Development
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
April 16, 2024
 · 
11 min read
Drug Development
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
January 5, 2024
 · 
10 min read
Drug Development
Dermavant Announces Positive Results from Phase 4 Open-Label Trial of VTAMA® (tapinarof) Cream, 1% for the Treatment of Plaque Psoriasis in the Head and Neck Region in Adults
December 6, 2023
 · 
10 min read
Drug Development
AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023
November 7, 2023
 · 
17 min read
Drug Development
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
November 6, 2023
 · 
3 min read
Drug Development
Dermavant Presents Positive Results from Phase 4 Open-Label Trial of VTAMA® (tapinarof) Cream, 1% for the Treatment of Intertriginous Plaque Psoriasis in Adults at 43rd Annual Fall Clinical Dermatology Conference
October 20, 2023
 · 
10 min read
Drug Development
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
October 17, 2023
 · 
8 min read
Drug Development
CEQUA® (cyclosporine ophthalmic solution) 0.09% Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients Switched From Restasis® (cyclosporine ophthalmic emulsion) 0.05%
October 12, 2023
 · 
10 min read
Drug Development
First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity
October 11, 2023
 · 
15 min read
Drug Development
CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis
September 21, 2023
 · 
5 min read
Business
Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar
August 1, 2023
 · 
15 min read
Drug Development
SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study
July 26, 2023
 · 
12 min read
Drug Development
Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients
July 20, 2023
 · 
10 min read
Drug Development
Akebia Therapeutics Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia® (ferric citrate) for In-Center and Home Dialysis Patients
June 29, 2023
 · 
7 min read
Drug Development
Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration
June 17, 2023
 · 
9 min read
Drug Development
ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care
June 5, 2023
 · 
13 min read
Drug Development
Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
April 10, 2023
 · 
9 min read
Load More